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Abstract
Background Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of
cancer patients but remains difﬁcult to recognize and diagnose. While increases in circulating levels of a number of
inﬂammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with
advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus,
we sought to assess potential biomarkers of cancer-induced cachexia in patients with earlier stages of disease.
Methods A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer pa-
tients undergoing attempted tumour resections. A high-sensitivitymultiplexwas used for increased sensitivity for nine cytokines.
Results Resectable pancreatic cancer patients with cachexia had low levels of canonical pro-inﬂammatory cytokines
including interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumour necrosis factor (TNF). Even in our more
sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only mono-
cyte chemoattractant protein-1 (MCP-1) was increased in treatment-naïve cachectic patients compared with weight stable
patients and identiﬁed as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were found to be decreased in the same cohort of treatment-naïve cachectic
patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers.
Conclusions Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not
associated with high levels of classical markers of systemic inﬂammation. However, cachectic, treatment-naïve patients have
higher levels of MCP-1, suggesting that MCP-1 may be useful as a biomarker of cancer cachexia.
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Introduction
Profound wasting of skeletal muscle and adipose tissue is
perhaps the most obvious side effect of advanced cancer. This
wasting, which is a part of the cancer cachexia syndrome,
affects approximately 50% of all cancer patients, and nearly
all patients with advanced disease.1,2 While it is difﬁcult to
quantify the number of patient deaths that result directly
from cachexia, it is clear that cancer cachexia is a signiﬁcant
contributor to both morbidity and mortality.3,4
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Pancreatic cancer patients have among the highest rates of
cachexia, with an estimated 80–90% of patients with
end-stage disease affected.4,5 Additionally, cachexia in pancre-
atic cancer patients is not only associated with end-stage
disease as in other cancers, as our own analysis demonstrated
that over 70% of newly diagnosed pancreatic cancer patients
meet cachexia criteria.6 Although nearly 70% of pancreas
cancers are diagnosed after they have become unresectable,
even pancreatic cancer patients undergoing resection have
cachexia, and estimates indicate that 40% of pancreatic cancer
patients considered candidates for resection already exhibit a
10% body weight loss.7–10 Even in patients with resectable
disease, cachexia is associated with poor outcomes and
decreased survival.11
While the signiﬁcance of cancer cachexia is clear, this
syndrome remains under-recognized due to the high reliance
on self-reported weight loss, which has poor reliability.12–14
Further, the levels of weight loss associated with poor
outcomes are often not considered clinically meaningful.5,15
Thus, a biomarker of cancer cachexia would be a valuable
tool to improve the recognition of this syndrome.
A number of pro-inﬂammatory cytokines are associated
with cancer cachexia and thus considered potential bio-
markers.16–19 However, published data demonstrate that such
associations were largely made in patients with advanced
disease, including many in patients whom were undergoing
treatment, often second-line or third-line chemotherapy.
Further, patients with advanced disease commonly have
multiple causes of high systemic inﬂammation, making it
difﬁcult to differentiate cytokines associated with cachexia
from cytokines associated with cancer progression.
In an effort to establish a more direct relationship between
speciﬁc circulating factors and cancer cachexia, we set out to
proﬁle the landscape of a number of soluble factors in
pancreatic cancer patients undergoing an attempted resection
of their tumour. Using a multiplex array platform, we were
surprised to ﬁnd that cytokines traditionally associated with
cachexia, including tumour necrosis factor (TNF), interleukin-6
(IL-6), interleukin-1β (IL-1β), and Interferon-γ (IFN-γ), were
present in the circulation at low levels and did not associate
with cachexia. However, using this same platform and validated
by enzyme-linked immunosorbent assay (ELISA), we found that
the cytokine monocyte chemoattractant protein-1 (MCP-1),
also referred to as C-C Motif Chemokine Ligand 2 (CCL2), was
associated with cancer cachexia in treatment-naïve patients.
Materials and methods
Generation of the patient cohort
Patients undergoing attempted pancreatic resections at The
Ohio State University Wexner Medical Center were asked
to participate in a tissue banking protocol under which
blood was deposited into a tissue bank run by The Ohio
State University Comprehensive Cancer Center Pancreatic
Cancer Cachexia Program. The Ohio State Cancer Institu-
tional Review Board approved all experimental procedures
(IRB 2010C0051). All study participants provided informed
consent. Between November 2013 and November 2015,
intraoperative peripheral blood was collected from 84
patients diagnosed with pancreatic adenocarcinoma who
were undergoing surgical evaluation. From this total,
patients who were undergoing operations other than
attempted resection of their tumour (n = 3), patients with
a ﬁnal pathological diagnosis of adenosquamous carcinoma
(n = 4), and patients with an ampullary tumour (n = 3)
were excluded. Two patients were excluded because of un-
clear documentation of weight loss. Patients were classiﬁed
as either weight stable or cachectic, deﬁned as weight loss
of >5% of their pre-illness weight, which is consistent with
the diagnostic criteria of the international consensus deﬁni-
tion of cancer cachexia.20 Although patients were asked to
estimate the time period over which they had lost weight,
patients were considered cachectic based upon losses from
their pre-illness weight, regardless of the time course over
which the weight was lost. Two patients who reported
weight loss of <5% were excluded from the study, as nei-
ther of these patients met the secondary criteria of low
body mass index (BMI) or low appendicular muscle mass.
Patients were considered weight stable if they denied
weight loss in their preoperative surgical consultation and
no documentation of weight loss could be located within
his or her existing Ohio State Medical Center medical re-
cord. These exclusions left a ﬁnal total of 70 patients for
analysis. Patients were considered treatment-naïve if they
had not received chemotherapy or radiation prior to
surgical exploration for this incidence of cancer. A previous
history of a cancer other than pancreatic cancer was not an
exclusionary criterion. Further, we did not exclude patients
based upon any medications. Although we did not track
their use, at Ohio State University, a standard protocol is
used prior to surgery, including withholding statins 1 day
prior to surgery and NSAIDS 5 days prior to surgery.
Clinical characteristics of the patients included in our study
appear in Table 1.
Blood collection
Peripheral blood was collected intraoperatively in heparinized
tubes from consented patients under anaesthesia. The ﬁnal
concentration of heparin was approximately 15 USP per mL
of blood. Plasma was produced by centrifugation at 500 g for
10 min, then aliquoted and stored at 80°C until batched
analysis.
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Multiplex analyses
Our initial screen of 25 cytokines and growth factors was con-
ducted using a custom ProcartaPlex (eBioscience) Luminex
Multiplex Panel. Our custom platform contained 25 factors
(25plex) that we identiﬁed as either previously associated
with cachexia in patients with advanced disease or that we
hypothesized may be associated with cancer cachexia, based
on the literature. Our screen included 18 cytokines, 5 growth
factors, 1 enzyme, and 1 hormone. A list of the soluble
factors assessed appears in Table 2. For increased sensitivity,
we also used a High Sensitivity 9-Plex Human ProcartaPlex
Panel (eBioscience). Both panels were assayed in accordance
with the manufacturer’s instructions.
ELISA analysis
Differences in MCP-1 between weight stable and cachectic
patients were conﬁrmed using an eBioscience ELISA accord-
ing the manufacturer’s instructions using a Biotek Synergy
HT multiplate reader and Gen5 software. Samples were run
on two plates of the same lot, and data were ﬁt to a standard
curve using four-parameter logistic regression.
Data analysis and statistics
Differences in continuous clinical variables between cachectic
and weight stable patients were assessed using Student’s
t-tests, and differences in categorical variables were assessed
using Fisher’s exact tests. Differences in tumour stage be-
tween groups was assessed using a Mann–Whitney U test.21
For cytokine data, our analysis strategy using both continuous
and categorical variables was modiﬁed from Lerner et al.17
For soluble factors where <25% of patients reached the
lower limit of quantitation, no analysis was performed.
Factors for which >75% of patients tested exceeded the
lowest standard were analysed as continuous variables.
Remaining factors detected in >25% of patients but exceed-
ing the lowest standard in <75% of patients were analysed as
categorical variables based upon if a given patient exceeded
the lowest standard or not. For continuous variables, all
statistical tests were performed on log-transformed cytokine
values to reduce the effect of skew. Two-tailed, unpaired
t-tests were used when making comparisons between weight
stable and cachectic patients. For categorical variables, be-
cause of the relatively small sample sizes, Fisher’s exact tests
were used. For MCP-1 ELISA data with more than two groups,
one-way ANOVA was used. Relationships between weight
loss or BMI and plasma cytokine concentrations were deter-
mined using simple linear regressions. A priori, alpha was
set at P < 0.05. The relationship between circulating MCP-1
and survival was assessed by dividing patients into high and
low MCP-1 groups using the median MCP-1 level, as
Table 2 Soluble factors analysed
CD40L IL-1β PDGF-BB
FGF-2 IL-4 RANKL
G-CSF IL-6 SDF-1α
GM-CSF IL-8 TGFα
HGF Leptin TNF
IFN-γ LIF TRAIL
IL-10 M-CSF VEGF-A
IL-15 MCP-1
IL-17A MMP-13
Table 1 Patient characteristics
Weight stable (n = 22) Cachectic (n = 48) t-test
Mean age (±SD) 64.6 ± 10.8 67.6 ± 10.2 P = 0.27
Male (%) 10 (45) 23 (48) P = 1.00
Mean pre-illness BMI (±SD) 27.6 ± 5.3 30.1 ± 7.4 P = 0.15
Mean BMI at time of surgery (±SD) 27.6 ± 5.3 26.2 ± 6.1 P = 0.36
Median weight loss (%) 0 10% P < 0.05
History of hypertension 11 (50) 32 (67) P = 0.20
History of diabetes 4 (18) 21 (44) P = 0.06
Clinical tumour stage
1A (%) 1 (5) 0 (0) P = 0.998
2B (%) 12 (54) 31 (64)
3 (%) 6 (27) 8 (17)
4 (%) 3 (14) 9 (19)
Neoadjuvant-treated (%) 11 (50) 14 (29) P = 0.11
Treatment:
Chemotherapy: folﬁrinox 7 (64) 9 (64)
Chemotherapy: gemcitabine-abraxane 3 (27) 5 (36)
Gemcitabine-cisplatin 1 (9) 0 (0)
Chemo/radiation 9 (82) 12 (86) P = 0.79
Resected (%) 19 (86) 37 (77) P = 0.59
Treatment-naïve, resected (%) 11 (50) 27 (56) P = 0.80
BMI, body mass index; SD, standard deviation.
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determined by ELISA. One patient who died within 30 days of
surgery was excluded from the analysis, as this death was
presumed to result from operative complications. Patients
were censored from analysis at the date of their last known
visit to The Ohio State Wexner Medical Center through April
2017. Differences in overall survival between groups were
assessed using a log-rank test. Differences in survival at 1 year
were assessed using a Fisher’s exact test. Statistical analysis
was conducted with GraphPad Prism 6.0.
Results
Resectable pancreatic cancer patients have low
levels of canonical pro-inﬂammatory cytokines
In an effort to identify a biomarker associated with cancer
cachexia, we used a multiplex assay to compare levels of 25
soluble factors in plasma of 70 pancreatic adenocarcinoma
patients undergoing an attempted resection of their tumour.
Patients were classiﬁed either as weight stable or cachectic,
with cachexia deﬁned as weight loss of >5% of their
pre-illness weight, consistent with the diagnostic criteria of
the international consensus deﬁnition of cancer cachexia.20
Of the 25 tested soluble factors, 13 reached the lower limit
of quantitation in <25% of patients (see Supporting
Information, Table S1). Because of the low number of pa-
tients with detectable values of these cytokines, no analyses
were performed on these cytokines. Surprisingly, this group
of soluble factors included IL-6, IFN-γ, and IL-1β, which have
traditionally been associated with cachexia.
Our remaining 12 cytokines were analysed as either
continuous or categorical variables, based upon the
proportion of patients with plasma levels that exceeded the
lowest standard for each cytokine (see Supporting Informa-
tion, Table S1). For the eight cytokines with >75% of patients
exceeding the lowest standard, differences in cytokine levels
between cachectic and weight stable patients were analysed
as continuous variables (Figure 1). To reduce skew, all
statistical analysis was conducted on log-transformed values.
Of these eight soluble factors, only leptin was signiﬁcantly
decreased in cachectic patients compared with weight stable
ones. This ﬁnding is consistent with a number of other
reports.19,22,23 TNF, another cytokine commonly associated
with cancer cachexia,17 was not signiﬁcantly different
between groups in this patient population.
For our ﬁnal four soluble factors, for which plasma levels
were detectable in >25% of patients yet >25% of patients
were below the lowest standard, data were converted to
categorical variables of above or below the lowest standard
and assessed using a Fisher’s exact test. No signiﬁcant
differences existed in the proportion of patients with
Figure 1 Soluble factors analysed as continuous variables. Differences between weight stable and cachectic patients were assessed using a Student’s
t-test on log-transformed values to eliminate skew. N = 70 patients with pancreatic cancer. Solid line indicates mean. * indicates P < 0.05.
A. D.B. C.
E. F. G. H.
p=0.87p=0.96
p=0.17 p=0.89 p=0.28
p=0.95
*
p=0.25
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measureable TNF-related apoptosis-inducing ligand (TRAIL),
matrix metalloproteinase-13 (MMP-13), ﬁbroblast growth
factor 2 (FGF2), or interleukin-8 (IL-8) (Table 3).
Our original intention was to proﬁle all patients undergoing
an attempted resection of their pancreatic tumour, as this
would be the data available to a clinician when the decision
to attempt a resection is made. However, as noted above, in
a number of cachexia biomarker studies, cachectic patients
appeared to have more advanced disease.17 While we
attempted to control for disease progression by only enrolling
patients into this study with potentially resectable tumours,
14 of 70 patients (3 weight stable, 11 cachectic) did not have
their tumours resected either due to distant metastases or
the ﬁnding of an anatomically unresectable tumour. When we
analysed the remaining 56 resected patients, we found similar
results to our 70-patient cohort, with the sole difference being
leptin that only tended to decline in cachectic patients
(see Supporting Information, Figure S1; Table S2).
From these results, we were struck by the lack of differences
in so many pro-inﬂammatory cytokines that had been previ-
ously associated with cancer cachexia. We considered the
possibility that our inability to detect such differences was
due to a lack in sensitivity in the multiplex platform. To address
this concern, we performed a high-sensitivity multiplex in our
population of 56 resected patients for nine cytokines, which
included IL-6, IFN-γ, IL-1β, and TNF. This assay has quantitation
limits that are approximately 10-fold lower than the custom
25plex. Using a similar analysis strategy as for our previous
multiplex platform, four cytokines (IL-4, IL-6, IL-10, and TNF)
were analysed as continuous variables, as >75% of samples
exceeded the lowest standard. We identiﬁed that IL-10 was
increased in cachectic patients (Figure 2), which is consistent
with previous reports.17,18 However, no signiﬁcant differences
in IL-4, IL-6, or TNF were present between cachectic and weight
stable pancreatic cancer patients with resectable disease
(Figure 2). Similarly, the remaining ﬁve cytokines (IL-1β, IL-2,
IL-12p70, IL-17a, and IFN-γ) were analysed as categorical
variables, and there were no signiﬁcant differences in propor-
tion of patients with detectable levels (Table 4). These data
strongly suggest that in patients with resectable pancreatic
cancer, cachexia is not associated with high levels of canonical
pro-inﬂammatory cytokines.
Effect of neoadjuvant therapy on circulating
factors
Given that developing tumours are associated with increases
in many of the same soluble factors that have been
associated with cachexia, we considered that neoadjuvant
chemotherapy and/or radiation therapy of tumours prior
to surgery could alter the circulating levels of these factors.
Table 3 Soluble factors analysed as categorical variables
Proportion of patients reaching lowest standard (%)
Soluble factor Weight stable Cachectic
Fisher’s exact
test
TRAIL 17/22 (77) 33/48 (69) P = 0.57
MMP-13 12/22 (55) 34/48 (71) P = 0.28
FGF-2 10/22 (45) 29/48 (60) P = 0.30
IL-8 4/22 (18) 17/48 (35) P = 0.17
FGF-2, ﬁbroblast growth factor 2; IL-8, interleukin-8; MMP-13, ma-
trix metalloproteinase-13; TRAIL, apoptosis inducing ligand.
Figure 2 Soluble factors analysed as continuous variables from the high-
sensitivity multiplex. Differences between weight stable and cachectic
patients were assessed using a Student’s t-test on log-transformed values
to eliminate skew. N = 56 resected patients. Solid line indicates mean. *
indicates P < 0.05.
B.A.
D.C.
p=0.11
p=0.59
p=0.78
Table 4 High sensitivity cytokines analysed as categorical variables
Proportion of patients reaching lowest standard (%)
Soluble factor Weight stable Cachectic
Fisher’s exact
test
IL-1β 7/19 (37) 15/37 (41) P = 1.00
IL-2 11/19 (58) 21/37 (57) P = 1.00
IL-12p70 11/19 (58) 22/37 (59) P = 1.00
IL-17A 12/19 (63) 21/37 (57) P = 0.78
IFN-γ 7/19 (37) 15/37 (41) P = 1.00
IFN, interferon; IL, interleukin.
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Indeed, when we assessed levels of soluble factors only in
resected, treatment-naïve patients (n = 38), we observed
that both leptin and granulocyte-macrophage colony-
stimulating factor (GM-CSF) were signiﬁcantly decreased in
cachectic patients compared with weight stable patients
(Figure 3A and D). Further, MCP-1, tended to be increased
in cachectic patients (P = 0.05, Figure 3G). No signiﬁcant dif-
ferences between cachectic and weight stable treatment-
naive patients were identiﬁed in any other analysed
cytokine (see Supporting Information, Table S3). Further,
analysis of the high-sensitivity multiplex data for resected,
treatment-naïve patients also did not identify any signiﬁcant
differences between cachectic and weight stable patients
(see Supporting Information, Table S4).
Upon closer examination, we identiﬁed a strong relation-
ship between leptin and weight loss in our population of
successfully resected, treatment-naïve patients (Figure 3B).
These data are consistent with many other reports
Figure 3 Leptin, granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein-1 (MCP-1) are associated with
pancreatic cancer-induced cachexia in resected treatment-naïve pancreatic cancer patients. Differences in (A) leptin, (D) GM-CSF, and (G) MCP-1
between weight stable and cachectic patients were assessed using a Student’s t-test on log-transformed values to eliminate skew. An inverse
relationship exists between increasing weight loss and both (B) leptin and (E) GM-CSF, while MCP-1 tends to have a positive relationship with
increasing (H) weight loss. Finally, while circulating (C) leptin and (F) GM-CSF levels are associated with BMI, (I) MCP-1 levels did not. N = 38 resected,
treatment-naïve patients. Solid line indicates mean. * indicates P < 0.05.
A.
G.
D.
*
*
p=0.05
B.
H.
E.
C.
I.
F.
R2 = 0.001
p=0.869
R2 = 0.067
p=0.117
R2 = 0.227
p=0.004
R2 = 0.122
p=0.042
R2 = 0.158
p=0.014
R2 = 0.112
p=0.040
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demonstrating a strong inverse relationship between
circulating leptin and weight loss, which includes cancer
patients with cachexia.23 However, although associated with
weight loss, the ability of leptin to be used as a biomarker in
cancer cachexia is limited by its strong positive association with
BMI,24–26 which was also identiﬁed in our patient population
(Figure 3C). Thus, a cachectic patient with a high BMI may still
have a high leptin level and likely would not meet the criteria to
be diagnosed as cachectic based on leptin alone, limiting the
utility of leptin as a biomarker of cancer cachexia.
Our analysis also revealed a novel association between
GM-CSF and cancer cachexia, including a linear relationship
between plasma GM-CSF levels and weight loss (Figure 3E).
However, similar to leptin, GM-CSF was also tightly associated
with BMI (Figure 3F). Thus, GM-CSF is also unlikely to serve as
a useful biomarker of cancer cachexia, as it also serves as an
indicator of BMI.
In contrast, while circulating MCP-1 levels only exhibited a
modest trend towards a relationship with weight loss
(P = 0.11, Figure 3H), no relationship existed between plasma
MCP-1 and BMI (Figure 3I). Thus, unlike leptin and GM-CSF,
MCP-1 appears not to simply serve as a surrogate marker of
a patient’s BMI but may instead be considered as a potential
biomarker for the diagnosis of cancer cachexia in treatment-
naïve pancreatic cancer patients.
MCP-1 as a potential biomarker of cancer cachexia
Although circulating MCP-1 has been shown to be elevated in
patients with pancreatic cancer,27,28 as far as we are aware,
increased circulating MCP-1 has never been associated with
cancer cachexia. To conﬁrm our ﬁndings, we used a commer-
cially available ELISA. Similar to our multiplex data, MCP-1
was higher in cachectic, treatment-naïve patients vs. weight
stable treatment-naïve patients (Figure 4A). When we
stratiﬁed cachectic patients by weight loss, MCP-1 was found
to be higher in patients having lost 5–10% of their body
weight compared with weight stable patients, whereas
patients with more severe weight loss (>10%) were not
different from either weight stable or moderately cachectic
(5–10% weight loss) patients (Figure 4B).
In some studies, increased circulating MCP-1 has been
associated with increased BMI.29–31 However, in our cohort
of 38 chemotherapy-naïve, successfully resected patients,
neither BMI at time of surgery nor pre-illness BMI associated
with plasma MCP-1 as determined by ELISA (see Supporting
Information, Figure S2A and B). Metabolic syndrome, and
speciﬁcally diabetes, has also been associated with increased
circulating MCP-1.32 When we subdivided our patients based
upon their diabetes status, we still identiﬁed a signiﬁcant
main effect for cachexia, but no main effect for diabetes or
interaction effect for diabetes and cachexia (see Supporting
Information, Figure S2C).
Finally, because MCP-1 has been positively associated
with survival in pancreatic cancer patients, we assessed if
there was a relationship between MCP-1 and survival in
our patient population.27,33 When we divided patients into
high and low MCP-1 groups using the ELISA MCP-1 values,
Figure 4 Monocyte chemoattractant protein-1 (MCP-1) as a biomarker
for pancreatic cancer-induced cachexia. Increased (A) MCP-1 in cachectic
pancreatic cancer patients was conﬁrmed by ELISA. (B) MCP-1 levels are
signiﬁcantly increased in patients who have lost 5–10% of their body
weight compared with weight stable patients but not in those who had
lost >10%. (C) Circulating MCP-1 is not associated with survival in treat-
ment-naïve patients with R0 resections. N = 38 successfully resected,
treatment-naïve patients. Solid line indicates mean. * indicates
P < 0.05 vs. weight stable.
*
*
B.
C.
p=0.85
A.
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we did not ﬁnd a difference in survival between groups (low
MCP-1 median survival 522 days, high MCP-1 median sur-
vival 447 days, Figure 4C). To ensure that disease burden
was not a contributing factor to this ﬁnding, we repeated
our analysis including only patients that had R0 resections
with negative margins, meaning that these patients had no
known disease following surgery (n = 24). We again found
no signiﬁcant difference in survival between groups (low
MCP-1 median survival 745 days, high MCP-1 median sur-
vival 640 days). However, for patients in this group with at
least 1 year of follow-up, the proportion of patients surviv-
ing 1 year did tend to be higher in patients with low
MCP-1 (low MCP-1, 10 out of 11 alive; high MCP-1, 6 out
of 10 alive; P = 0.14).
Discussion
Cancer cachexia is commonly associated with increased
levels of circulating inﬂammatory cytokines such as TNF, IL-
1β, IL-6, and IFN-γ.16–19 However, these associations were
made in patients with late-stage cancer, which is inﬂuenced
by a number of potential confounders that may contribute
to systemic inﬂammation. Thus, one cannot exclude the pos-
sibility that these elevated inﬂammatory cytokines in ca-
chectic patients result from advanced disease, rather than
directly from the cachexia syndrome. Our data using a co-
hort of both potentially resectable and resected pancreatic
cancer patients demonstrate that circulating levels of
inﬂammatory cytokines such as TNF, IL-6, IL-1β, and IFN-γ,
which have previously been considered markers of cancer
cachexia, are actually quite low, and furthermore, did not
associate with cachexia in this tumour type. However,
differences in leptin, GM-CSF, and MCP-1 were associated
with cachexia. While circulating levels of leptin and GM-
CSF are closely related to a patient’s BMI, MCP-1 levels do
not simply report BMI, revealing MCP-1 as a potential bio-
marker of cancer cachexia.
Decreased leptin and GM-CSF are associated with
cachexia in pancreatic cancer
Leptin has been previously identiﬁed to be elevated in cancer
patients with a number of tumour types, including pancreatic
cancer, compared with healthy controls.23,25 However, leptin
levels of cachectic patients are generally lower than weight
stable cancer patients or healthy controls.19,22–24 While large
cohort studies repeatedly demonstrate that leptin levels
correlate with weight loss,24–26 leptin levels in the same
studies are also highly correlated with the subject’s BMI.
Thus, on the basis of diagnosing an individual patient with
cachexia using a single blood draw, leptin is not without
challenges, particularly in cancers like pancreatic cancer,
where patients often have high BMIs, even after developing
cachexia. One study did identify that leptin levels were lower
in cachectic patients than would be predicted by their BMI,26
but this additional analysis complicates the use of leptin as
an indicator of cachexia.
Although GM-CSF is an area of intense interest in pancre-
atic cancer patients, as GM-CSF appears to contribute to the
immune suppression that allows pancreatic cancer to
develop and progress,34–36 we were unable to ﬁnd any study
reporting changes in plasma GM-CSF in pancreatic cancer
patients. Further, we were unable to identify any reports
demonstrating differences in circulating GM-CSF between
cachectic and weight stable patients in any cancer type.
Thus, to the best of our knowledge, this is the ﬁrst study
to associate circulating GM-CSF to cancer cachexia.
Importantly, while associated with weight loss, similar to
leptin, GM-CSF was also tightly associated with BMI in our
cohort of patients. Thus, we can conclude that similar to
leptin, GM-CSF is unlikely to be useful as a biomarker of
cancer cachexia.
MCP-1 as a potential biomarker of cancer cachexia
MCP-1 is a ubiquitously expressed gene, including expression
in adipose tissue, skeletal muscle, and pancreatic tumours.
Increased MCP-1 gene expression in both tumours and adi-
pose tissue has been previously associated with cancer ca-
chexia, either preoperatively or post-operatively, although
contrasting data exist for adipose messenger RNA.37–39
Our data are the ﬁrst to associate increased circulating
MCP-1 with cancer cachexia. Previously, MCP-1 was found
not to associate with cachexia either in a large cohort of
mixed tumour types17,18 or lung or pancreatic cancer pa-
tients.40 The lack of differences in these studies between
cachectic and weight stable patients could be due to the
inclusion of patients who had previously received therapy
for their disease. This would be consistent with our own re-
sults, as inclusion of neoadjuvantly-treated patients masked
differences in MCP-1 between cachectic and weight stable
patients. Thus, chemotherapy and/or radiation treatment
may decrease circulating levels of this factor.
A second possible explanation for the difference between
our ﬁndings and previous results is that circulating MCP-1
could be an indicator of initiating cachexia. Data from our
institution demonstrate that higher MCP-1 is actually
predictive of increased, not decreased survival in untreated
metastatic pancreatic cancer patients.33 These ﬁndings
suggest that there may be differences in the biology of
MCP-1 throughout the progression of PDAC.
Obesity and diabetes are common in cancer patients and
particularly common in pancreatic cancer patients.41 Both obe-
sity and diabetes are important considerations in the utility of
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MCP-1 as a biomarker of cancer cachexia, as both these condi-
tions have been linked to increased circulating levels of MCP-1,
although a signiﬁcant body of literature exists where an associ-
ation between obesity and diabetes and high MCP-1 were not
demonstrated.29–32,42–47 Speciﬁcally in pancreatic cancer pa-
tients undergoing resection, an association was found between
high circulating MCP-1 and a BMI ≥37.5 kg/m2.28 Because this
study did not assess weight loss, it is not possible to determine
if patients with high BMIs weremore likely to be cachectic. Spe-
ciﬁcally within our dataset, we had three patients with a BMI
over 37.5 kg/m2 at the time of resection. Each of these patients
was classiﬁed as cachectic, and circulating MCP-1 levels for
each of these patients were below the mean of the cachectic
group.
Similar to the controversy surrounding increased circulat-
ing MCP-1 in obesity, conﬂicting animal studies exist
surrounding the role of MCP-1 in adiposity and metabolic
syndrome, with some studies suggesting MCP-1 exacerbates
the effect of high-fat feeding and others suggesting a protec-
tive effect of MCP-1.48–53 While the increase in circulating
MCP-1 in cachectic patients would suggest that MCP-1 might
prevent obesity, clearly, much remains to be understood
about the role of MCP-1 in body weight control.
In terms of the source of circuiting MCP-1 in cachectic
pancreatic cancer patients, adipose tissue produces MCP-
1, including in cachectic cancer patients.37,39 Thus, it is
tempting to speculate that the increase in circulating
MCP-1 in cachectic patients results from breakdown of ad-
ipose tissue. However, our current dataset does not allow
us to associate changes in adipose tissue mass with
MCP-1. More in-depth analysis will be required to properly
address this question.
Limitations and lessons learned in attempting to
identify a biomarker of cancer cachexia
Like any study, ours is not without limitations. Because we
have chosen to focus on only patients undergoing an
attempted resection with a single tumour type, our study
cohort is relatively small, particularly after excluding pa-
tients who failed to be resected or received neoadjuvant
therapy. Future work will be required to validate MCP-1
as a potential biomarker in a much larger cohort, including
careful assessments of sex, age, and other conditions.
Additional work will also be required to determine if
MCP-1 is a biomarker of cancer cachexia in other cancers
or is speciﬁc to pancreatic cancer.
Through the course of this study, we gained an apprecia-
tion for several important factors that need to be considered
when attempting to identify a biomarker of cancer cachexia.
In addition to taking into account disease progression,
treatment status is an important variable of any biomarker
study, which traditionally has been underappreciated in the
search for a biomarker of cancer cachexia. A potential
limitation to any biomarker of cachexia is how it is altered
by systemic therapy, as the development of cachexia could
be masked by anticancer treatment. However, it is important
to remember that cachexia can be assessed in a number of
ways in patients undergoing treatment for their disease,
including with regularly collected weight data and via analysis
of muscle and adipose tissue volumes by radiographic
imaging.54,55 The true utility of a biomarker of cancer
cachexia is at the time of initial diagnosis, when patients
often lack weight data or imaging to provide a baseline from
which to assess cachexia. For this reason, it will be important
for future studies when attempting to identify a cachexia
biomarker to do so in a patient population most likely to
beneﬁt from such a discovery—those that are treatment-
naïve. Future studies need to be conducted in patients across
the cancer spectrum, so long as disease burden is carefully
controlled for between weight stable and cachectic groups.
This is particularly important in cancers such as pancreatic
cancer, where 70% of patients already have unresectable
disease at the time of diagnosis.9,10
Another important unexpected ﬁnding in our study was
the overall low levels of our tested soluble factors in resect-
able pancreatic cancer patients that were obtained using a
multiplex array platform. Thus, caution should be exercised
when undertaking future studies using similar soluble factor
multiplexing methodologies, as the limits of detection of this
technology can be quite high.56,57 This is particularly relevant
when including healthy control patients in study designs, as
levels of soluble factors are likely to be even lower in these
patients. Thus, we strongly suggest that results using such
platforms undergo rigorous validation.
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